NASDAQ$KRYS

Krystal Biotech Inc · Q1 2017 earnings

Q1 2017 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.12

No prior period
Net Income

-$494K

No prior period
Operating Income

-$465K

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$319K

No prior period

Revenue & EPS history

Krystal Biotech · Revenue · Quarterly

$116M

Q1 2026+31.9%vs Q1 2025
Beat estimate in 6 of 11 quarters(55%)
ActualEstimate

Revenue by segment

Krystal Biotech · $91.1M total across 1 segment · Q4 2024

  • VYJUVEK Net Product Revenue
    $91.1M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+1.3%

Avg return

Earnings day

+1.8%

Avg return

5 days after

+9.5%

Avg return

30 days after

54%

19 / 35 earnings

Positive

+52.8%

Q4 2023

Best reaction

-14.0%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%+14.9%+13.3%
Q4 2025+4.0%-5.3%-6.7%
Q3 2025+4.9%+0.2%+10.1%
Q2 2025-14.0%-11.7%-4.3%
Q1 2025-13.8%-18.6%-18.3%
Q4 2024+12.4%+19.3%+19.4%
Q3 2024-1.1%+13.2%+6.4%
Q2 2024-6.9%-5.1%-3.1%
Q1 2024+0.4%-3.9%+4.1%
Q4 2023+52.8%+50.7%+59.2%
Q3 2023-10.7%-19.3%-16.1%
Q2 2023-6.7%-4.2%-0.2%
Q1 2023+9.0%+4.7%+51.2%
Q4 2022+4.4%+0.7%+2.0%
Q3 2022+7.7%+4.7%+1.6%
Q2 2022-5.2%-3.4%-17.1%
Q1 2022-4.7%+0.4%+15.4%
Q4 2021+2.6%-8.2%+7.0%
Q3 2021-7.4%-7.4%+48.5%
Q2 2021-1.6%-6.2%-3.2%
Q1 2021-7.2%-4.0%-7.6%
Q4 2020+6.8%-7.8%-2.3%
Q3 2020+2.6%+3.1%+35.0%
Q2 2020+0.5%+6.7%+11.7%
Q1 2020+13.7%+25.3%+3.8%
Q4 2019-0.7%-12.0%-12.0%
Q3 2019+1.6%+0.5%+43.5%
Q2 2019-4.0%-3.3%-6.2%
Q1 2019+2.6%+14.6%+1.1%
Q4 2018-4.1%+1.9%+55.6%
Q3 2018-4.7%-1.5%+5.4%
Q2 2018+2.7%+1.5%+6.1%
Q1 2018+0.1%+0.2%+23.5%
Q4 2017+5.8%+21.2%+2.9%
Q3 2017+6.0%+1.9%+4.1%
Q2 2017
Q1 2017
Q4 2016
Q3 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro